In MS mouse models, inducing this eIF2α phosphorylation-mediated adaptive capacity, either through genetic or pharmacological strategies, yields beneficial and protective effects in reducing EAE disease progression [27,29,30], plausibly driven by GCN2 activation. The gene discussed is EIF2A; the disease is myeloid sarcoma.